vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Rimini Street, Inc. (RMNI). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $105.5M, roughly 1.8× Rimini Street, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 1.2%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 1.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
AXSM vs RMNI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $105.5M |
| Net Profit | — | $1.4M |
| Gross Margin | — | 59.0% |
| Operating Margin | -33.1% | 4.6% |
| Net Margin | — | 1.3% |
| Revenue YoY | 57.4% | 1.2% |
| Net Profit YoY | — | -59.4% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $105.5M | ||
| Q4 25 | $196.0M | $109.8M | ||
| Q3 25 | $171.0M | $103.4M | ||
| Q2 25 | $150.0M | $104.1M | ||
| Q1 25 | $121.5M | $104.2M | ||
| Q4 24 | $118.8M | $114.2M | ||
| Q3 24 | $104.8M | $104.7M | ||
| Q2 24 | $87.2M | $103.1M |
| Q1 26 | — | $1.4M | ||
| Q4 25 | $-28.6M | $724.0K | ||
| Q3 25 | $-47.2M | $2.8M | ||
| Q2 25 | $-48.0M | $30.3M | ||
| Q1 25 | $-59.4M | $3.4M | ||
| Q4 24 | $-74.9M | $6.7M | ||
| Q3 24 | $-64.6M | $-43.1M | ||
| Q2 24 | $-79.3M | $-1.1M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | — | 60.4% | ||
| Q3 25 | — | 59.9% | ||
| Q2 25 | — | 60.4% | ||
| Q1 25 | — | 61.0% | ||
| Q4 24 | — | 63.7% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | -33.1% | 4.6% | ||
| Q4 25 | -13.8% | 4.5% | ||
| Q3 25 | -27.0% | 4.2% | ||
| Q2 25 | -24.5% | 39.6% | ||
| Q1 25 | -46.9% | 9.0% | ||
| Q4 24 | -61.1% | 13.0% | ||
| Q3 24 | -59.8% | -47.4% | ||
| Q2 24 | -89.5% | -0.8% |
| Q1 26 | — | 1.3% | ||
| Q4 25 | -14.6% | 0.7% | ||
| Q3 25 | -27.6% | 2.7% | ||
| Q2 25 | -32.0% | 29.1% | ||
| Q1 25 | -48.9% | 3.2% | ||
| Q4 24 | -63.1% | 5.8% | ||
| Q3 24 | -61.7% | -41.2% | ||
| Q2 24 | -91.0% | -1.1% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $-0.55 | $0.00 | ||
| Q3 25 | $-0.94 | $0.03 | ||
| Q2 25 | $-0.97 | $0.32 | ||
| Q1 25 | $-1.22 | $0.04 | ||
| Q4 24 | $-1.54 | $0.07 | ||
| Q3 24 | $-1.34 | $-0.47 | ||
| Q2 24 | $-1.67 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $132.2M |
| Total DebtLower is stronger | $70.0M | $56.4M |
| Stockholders' EquityBook value | — | — |
| Total Assets | $713.6M | $397.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $132.2M | ||
| Q4 25 | $322.9M | $120.0M | ||
| Q3 25 | $325.3M | $108.7M | ||
| Q2 25 | $303.0M | $101.3M | ||
| Q1 25 | $300.9M | $122.6M | ||
| Q4 24 | $315.4M | $88.8M | ||
| Q3 24 | $327.3M | $119.5M | ||
| Q2 24 | $315.7M | $134.2M |
| Q1 26 | $70.0M | $56.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $-27.0M | ||
| Q3 25 | $73.7M | $-27.3M | ||
| Q2 25 | $73.1M | $-29.0M | ||
| Q1 25 | $53.2M | $-63.7M | ||
| Q4 24 | $57.0M | $-69.4M | ||
| Q3 24 | $92.9M | $-76.8M | ||
| Q2 24 | $102.9M | $-36.1M |
| Q1 26 | $713.6M | $397.1M | ||
| Q4 25 | $689.8M | $423.1M | ||
| Q3 25 | $669.3M | $352.9M | ||
| Q2 25 | $639.8M | $397.5M | ||
| Q1 25 | $596.7M | $343.0M | ||
| Q4 24 | $568.5M | $369.1M | ||
| Q3 24 | $561.5M | $343.8M | ||
| Q2 24 | $548.2M | $367.4M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
RMNI
Segment breakdown not available.
